Comparative investigation of the efficacy of Cortexin®, Pineamine®, levilimab, adalimumab, and dexamethasone on cytokine storm models

Download full text PDF
DOI: https://doi.org/10.29296/25419218-2021-06-08
Issue: 
6
Year: 
2021

A.V. Kalatanova(1), E.I. Trofimets(2), A.N. Afanasieva(1), V.B. Saparova(1), K.L. Kryshen(2), I.E. Makarenko(1) 1-ZAO «Pharm-Holding», 34A, Svyaz St., Strelna, Saint Petersburg 198515, Russian Federation; 2-PHARMACY HOUSE Research and Production Association, 245, Kuzmolovsky Settlement, Vsevolozhsky District, Leningrad Region 188663, Russian Federation

Introduction. During the coronavirus infection pandemic, there remains relevant to search for drugs that have a therapeutic effect on the cytokine storm as the main cause of complications in this disease in humans. Objective: to evaluate the efficiency of in vitro and in vivo administration of Cortexin® and Pineamine® versus levilimab, adalimumab, and dexamethasone against proinflammatory cytokines. Material and methods. In an in vitro experiment, a model of a lipopolysaccharide (LPS)-induced cytokine storm was created using the RAW 264.7 cell line, followed by measuring the level of TNFα in the culture medium. In an in vivo experiment, a murine model of septic shock was formed by a single intraperitoneal injection of LPS. The clinical condition and mortality of animals and their plasma level of proinflammatory cytokines IL-6 and TNFα were evaluated. Results. The in vitro study showed that Cortexin® and Pineamine® had a therapeutic effect on the level of TNFα in the culture medium. In the in vivo experiment, Cortexin® and Pineamine® decreased the severity of clinical signs of the disease and mortality in animals, exerted a therapeutic effect on IL-6 and TNFα levels in a cytokine storm, exceeding that for the comparison drug levilimab. Conclusion. Cortexin® and Pineamine® versus the comparison drug levilimab have shown a comparable or higher therapeutic activity in in vitro and in vivo models of cytokine storm. The results of the investigation and consideration of the safety profile and low cost of organic preparations have led to the conclusion that Cortexin® and Pineamine® are promising drug candidates for further design as an element of combination therapy or prevention of complications of diseases, the pathogenetic mechanism of which involves the overexpression of proinflammatory cytokines (including complications of the novel coronavirus infection COVID-19).
Keywords: 
cytokine storm
IL-6
TNFα
Cortexin®
Pineamine®
levilimab
adalimumab
References: 
  1. Lee D.W., Gardner R., Porter D.L. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124 (2): 188–95. DOI: 10.1182/blood-2014-05-552729
  2. Shipilov M. V. Molekuljarnye mehanizmy «tsitokinovogo shtorma» pri ostryh infektsionnyh zabolevanijah. Lechebnoe delo. 2013; 1: 81–5. [Shipilov M.V. Molecular mechanisms of the «cytokine storm» in acute infectious diseases. Lechebnoye delo. 2013; 1: 81–5 (In Russian)]
  3. García-Sastre A., Biron C.A. Type 1 interferons and the virus-host relationship: a lesson in detente. Science. 2006; 312 (5775): 879–82. DOI: 10.1126/science.1125676
  4. Channappanavar R., Fehr A.R., Zheng J. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 2019; 129 (9): 3625–39. DOI: 10.1172/JCI126363
  5. Borisova E.O. Pobochnye effekty sistemnoj gljukokortikosteroidnoj terapii. Prakticheskaja pul'monologija. 2004; 3: 14–8. [Borisova E.O. Side effects of systemic glucocorticosteroid therapy. Prakticheskaya pul'monologiya. 2004; 3: 14–8 (In Russian)]
  6. Komerdus I. V., Budul N.A., Chekanova A.V. Sistemnoe dejstvie gljukokortikoidnyh preparatov: v pomosch' vrachu obschej praktiki. RMZh. 2017; 25 (1): 45–8. [Komerdus I.V., Budul N.A., Chekanova A.V. Systemic action of glucocorticoid drugs: to help the general practitioner. RMZH. 2017; 25 (1): 45–8 (In Russian)]
  7. Gosudarstvennyj Reestr predel'nyh otpusknyh tsen. [Elektronnoe izdanie]. Rezhim dostupa: http://grls.rosminzdrav.ru/PriceLims.aspx [State Register of maximum selling prices. [Electronic resource]. Access mode: http://grls.rosminzdrav.ru/PriceLims.aspx (in Russian)]
  8. RAW 264.7 (ATCC® TIB-71™). [Electronic resource]. Access mode: https://www.lgcstandards-atcc.org/products/all/TIB-71.aspx?geo_country=ru#generalinformation
  9. Raschke W.C., Baird S., Ralph P., Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell. 1978; 15 (1): 261–7. DOI: 10.1016/0092-8674(78)90101-0
  10. Merly L., Smith S.L.. Murine RAW 264.7 cell line as an immune target: are we missing something? Immunotoxicol. 2017; 39 (2): 55–8. DOI: 10.1080/08923973.2017.1282511
  11. Shigemori S., Namai F., Yamamoto Y. et al. Genetically modified Lactococcuslactis producing a green fluorescent protein-bovine lactoferrin fusion protein suppresses proinflammatory cytokine expression in lipopolysaccharide-stimulated RAW 264.7 cells. J. Dairy Sci. 2017; 100 (9): 7007–15. DOI: 10.3168/jds.2017-12872
  12. Sardari M., Skuljec J., Yin D. et al. Lipopolysaccharide-induced sepsis-like state compromises post-ischemic neurological recovery, brain tissue survival and remodeling via mechanisms involving microvascular thrombosis and brain T cell infiltration. Brain. Behav. Immun. 2021; 91: 627–38. DOI: 10.1016/j.bbi.2020.10.015
  13. Alsharif K.F., Almalki A.A., Al-Amer O. et al. Oleuropein protects against lipopolysaccharide-induced sepsis and alleviates inflammatory responses in mice. IUBMB Life. 2020; 72 (10): 2121–32. DOI: 10.1002/iub.2347
  14. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. Guidance for Industry. Rockville: Food and Drug Administration. 2005.